A detailed history of Bryn Mawr Trust CO transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 218 shares of KRYS stock, worth $34,986. This represents 0.0% of its overall portfolio holdings.

Number of Shares
218
Holding current value
$34,986
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 25, 2024

BUY
$174.7 - $213.66 $38,084 - $46,577
218 New
218 $39,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.12B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Bryn Mawr Trust CO Portfolio

Follow Bryn Mawr Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bryn Mawr Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Bryn Mawr Trust CO with notifications on news.